Aim: The first review of advanced cell therapy trials with perinatal cells.
Materials & Methods: We compiled 281 clinical trials of advanced cell therapy with perinatal cells that were registered in 2005-2015.
Results: The most common cell source in these trials is cord blood, but the cell type that provides the mechanism of action in the majority of trials is mesenchymal stem/stromal cells. We analyze trends among the 15 parameters we compiled for these trials.
Conclusion: Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase. Researchers in different countries tend to work with a preferred cell source and cell type.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/rme-2017-0066 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!